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Abstract  A  signiﬁcant  portion  of  chronic  hepatitis  B  (HBV)  infected  patients  is  in  the  inactive
carrier state,  characterized  by  normal  transaminase  levels,  little  viral  replication  and  minimal
liver necroinﬂammatory  activity.  Diagnosis  is  made  after  at  least  one  year  of  regular  monitoring
and requires  lifelong  follow-up  to  conﬁrm  that  this  state  is  maintained.
Studying  the  natural  history  of  inactive  carriers  is  currently  hindered  by  the  small  number  of
studies on  patients  correctly  diagnosed  according  to  current  guidelines.
When correctly  deﬁned,  inactive  carrier  state  carries  a  very  good  prognosis  in  the  spectrum
of chronic  hepatitis  B  infection,  with  low  rates  of  reactivation,  hepatocellular  carcinoma  and
progression  of  disease  to  cirrhosis.  In  addition,  clearance  of  hepatitis  B  surface  antigen  is  more
common  in  inactive  carriers  compared  to  the  general  HBV  infected  population.  Reactivation
is more  likely  during  the  ﬁrst  years  of  follow-up  and  during  immunosuppressive  therapies.
Prophylactic  antiviral  treatment  should  be  initiated  as  soon  as  possible  in  this  latter  case.
Current guidelines  do  not  routinely  recommend  liver  biopsy  in  inactive  carriers.  However,
some may  have  signiﬁcant  hepatic  ﬁbrosis  at  diagnosis  and  cannot  therefore  be  classiﬁed  as
such; others  may  develop  ﬁbrosis  during  follow-up  and  consequentially  have  poorer  prognosis.
Despite some  limitations,  transient  elastography  appears  an  ideal  approach  for  identifying  such
patients and  for  serial  monitoring  of  liver  changes  in  all  inactive  carriers.
Overall, more  longitudinal  studies  on  larger  cohorts  of  true  inactive  carriers  would  be  helpful
for establishing  with  greater  certainty  the  most  appropriate  management  strategy  in  these
patients.
© 2014  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.∗ Corresponding author.
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PALAVRAS-CHAVE
Hepatite  B  crónica;
Portador
Portadores  inativos  de  hepatite  B:  uma  populac¸ão  negligenciada?
Resumo  Uma  porc¸ão  signiﬁcativa  dos  doentes  com  infecc¸ão  crónica  pelo  vírus  da  hepatite
B (HBV)  encontra-se  num  estado  de  portador  inactivo,  caracterizado  por  níveis  normais  de
transamínases,  baixa  taxa  de  replicac¸ão  vírica  e  actividade  necroinﬂamatória  hepática  mínima.
O diagnóstico  é  feito  após  pelo  menos  um  ano  de  monitorizac¸ão  periódica  e  requer  vigilância
por tempo  indeterminado  para  conﬁrmar  que  se  mantém.
O estudo  da  história  natural  dos  portadores  inacitvos  é  actualmente  diﬁcultado  pelo  número
limitado de  estudos  em  doentes  correctamente  diagnosticados  de  acordo  com  as  guidelines
actuais.
Quando corretamente  deﬁnido,  o  estado  de  portador  inativo  associa-se  a  um  excelente
prognóstico  dentro  do  espectro  da  infecc¸ão  crónica  por  HBV,  com  baixas  taxas  de  reactivac¸ão,
carcinoma  hepatocelular  e  progressão  para  cirrose.  Além  disso,  a  perda  do  antigénio  de  superfí-
cie da  hepatite  B  é  mais  frequente  em  portadores  inativos  do  que  na  generalidade  da  populac¸ão
infetada  pelo  VHB.  A  reativac¸ão  é  mais  provável  durante  os  primeiros  anos  de  seguimento  e  após
terapêuticas  imunossupressoras:  deve  ser  instituída  proﬁlaxia  antivírica  neste  segundo  caso.
As guidelines  actuais  não  recomendam  biópsia  hepática  por  rotina  em  portadores  inativos;
no entanto,  alguns  deles  podem  ter  ﬁbrose  hepática  importante  na  altura  do  diagnóstico,  não
podendo  ser  classiﬁcados  como  tal;  outros  podem  vir  a  desenvolvê-la,  tendo  consequentemente
pior prognóstico.  Apesar  de  algumas  limitac¸ões,  a  elastograﬁa  hepática  transitória  aﬁgura-
se como  um  método  ideal  para  identiﬁcar  estes  doentes  e  para  a  monitorizac¸ão  seriada  de
alterac¸ões hepáticas  em  todos  os  portadores  inativos.
Novos  estudos  longitudinais  em  verdadeiros  portadores  inativos  são  necessários  para  estab-
elecer com  maior  certeza  a  melhor  estratégia  nestes  doentes.
© 2014  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos
os direitos  reservados.
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(. Introduction
nfection  with  hepatitis  B  virus  (HBV)  affects  approximately
ne  third  of  the  world’s  population  during  their  lifetime.1 It
s  estimated  that  240  million  people  worldwide  have  chronic
BV  infection,  deﬁned  by  persistence  in  the  serum  of  its
urface  antigen  (HBsAg).  It  is  especially  prevalent  in  Sub-
aharan  Africa  and  East  Asia,  where  perinatal  transmission
ccounts  for  the  majority  of  infections.  Transmission  can
ccur  through  body  ﬂuids  such  as  blood,  semen  or  vagi-
al  secretions;  the  major  routes  of  infection  are  perinatal,
exual  and  blood-to-blood  contact.2
Following  acute  exposure  to  HBV,  the  natural  history  of
BV  infection  goes  sequentially  through  the  following  two
hases:
1)  the  immune-tolerant  phase  is  characterized  by  hepatitis
B  early  antigen  (HBeAg)  positivity  (a  serological  marker
of  viral  replication),  high  viral  replication  rate  (elevated
HBV  DNA  levels)  and  normal  alanine  aminotransferase
(ALT)  levels.  There  is  little  to  no  inﬂammation  or  ﬁbrosis
of  the  liver.  This  phase  tends  to  be  more  prolonged  in
perinatally  acquired  infection.
2)  in  the  immune-reactive  phase  the  host’s  immune  sys-
tem  starts  mounting  a  response  against  HBV:  replication
levels  lower,  with  a  parallel  serum  HBV  DNA  level  drop,
ALT  levels  rise  and  there  is  moderate  to  severe  necroin-
ﬂammatory  activity  in  the  liver.  This  phase  ends  with
HBeAg  loss  and  seroconversion  to  anti-HBe  status,  which
p
ois  usually  associated  with  viral  suppression  by  the  host’s
immune  system.1 The  likelihood  of  clearing  the  virus  and
curing  infection  during  this  phase,  evidenced  serologi-
cally  by  HBsAg  clearance,  depends  largely  on  patient’s
age  at  the  time  of  infection,  so  that  chronicity  occurs  in
80--90%  of  infected  newborns,  in  contrast  with  30--50%
if  infection  is  acquired  in  early  childhood  and  only  <5%
if  infected  in  adulthood.2
After  HBeAg  seroclearance,  two  disease  states,  not
necessarily  static,  are  possible:
3)  Some  patients  remain  in  an  inactive  carrier  (IC)  state,
deﬁned  by  the  European  Association  for  the  Study  of  the
Liver  (EASL)  as  fulﬁlling  the  following  criteria:  (1)  HBeAg
negativity;  (2)  anti-Hbe  positivity;  (3)  persistently  nor-
mal  ALT  (PNALT)  levels  (<40  IU/mL,  with  measurements
at  least  every  3--4  months  during  1  year);  (4)  serum  HBV
DNA  levels  <2000  IU/mL.
4)  Others  evolve  to  HBeAg-negative  chronic  hepatitis  B
(CHB),  usually  associated  with  precore  or  basal  core  pro-
moter  mutant  HBV,  in  which  viral  replication  and  hepatic
inﬂammation  persist  despite  seroconversion  to  anti-HBe
status.  It  is  characterized  by  ﬂuctuating  ALT  and  serum
HBV  DNA  levels  that  can  drop  below  IC  cut-off  levels,
despite  persistent  viral  replication  and  hepatic  inﬂam-
mation.
Differentiating  between  IC  and  CHB  status  is  of
aramount  importance  in  clinical  practice,  since  it  has  seri-
us  implications  in  follow-up,  management  and  prognosis.1
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2Hepatitis  B  inactive  carriers  
2. Deﬁnition of inactive chronic HBV  carriers
2.1.  HBA  DNA  and  ALT  cut-off  levels
At  the  Management  of  Hepatitis  B  workshop  in  2000,  an
arbitrary  level  of  20,000  IU/mL  was  adopted  as  the  serum
HBV  DNA  cut-off  level  distinguishing  active  and  inactive
chronic  hepatitis.3 After  it  was  demonstrated  that  this  cut-
off  would  misclassify  45  and  30%  of  active  CHB  based  on  one
or  three  serial  HBV  DNA  measurements,  respectively,4 major
guidelines  adopted  a  lower  serum  HBV  DNA  cut-off  value  of
2000  IU/mL.1,5 Still,  the  EASL  acknowledges  that  there  can
be  inactive  HBV  carriers  with  DNA  levels  between  2000  and
20,000  IU/mL.
Debate  on  the  value  that  best  discriminates  between
active  and  inactive  infection  is  ongoing.  Chen  et  al.  followed
64  inactive  carriers  who  maintained  PNALT  during  a  mean
follow-up  period  of  17.6  years  and  measured  HBV  DNA  levels
periodically  (minimum  of  5  measurements);  68%  had  at  least
one  HBV  DNA  level  >2000  IU/mL  (excluding  those  obtained
during  the  ﬁrst  year  of  follow-up).6
Because  HBV  DNA  levels  in  HBe-negative  active  hepati-
tis  can  ﬂuctuate  from  undetectable  to  >2,000,000  IU/mL5
and  some  inactive  carriers  occasionally  have  HBV  DNA  lev-
els  between  2000  and  20,000  IU/mL,  a  single  HBV  DNA  level
between  2000  and  20,000  IU/mL  appears  to  be  a  ‘‘gray
area’’  which  can  correspond  to  both  active  CHB  or  inac-
tive  carriers.  It  is  thus  important  for  the  clinician  to  be
aware  of  the  importance  of  serial  HBV  DNA  measurements
and  life-long  follow-up  to  conﬁrm  that  inactive  carrier  state
is  maintained.
Another  IC  state  diagnostic  criterion  has  recently  been
revised:  lower  ALT  upper  limit  of  normal  (ULN)  levels  of
30  IU/L  for  men  and  19  IU/L  for  women  were  proposed
based  on  its  95th  percentile  in  healthy  Italian  blood  donor
candidates.5 Indeed,  there  appear  to  exist  differences  in
viremia,  risk  of  reactivation  and  liver  histological  lesions
between  patients  with  low-normal  (<0.5  ×  ULN)  and  high-
normal  ALT  (0.5--1  ×  ULN),  as  a  review  by  Andreani  recently
summarized.7 However,  most  of  these  results  come  from
studies  on  chronic  HBV  populations  with  heterogeneous  sero-
logical  proﬁles  and  HBV  DNA  levels.  These  observations  may
therefore  not  extend  to  inactive  carriers,  especially  since
several  prospective  studies  on  HBe-negative  carriers  with
PNALT  have  failed  to  demonstrate  signiﬁcant  differences
in  clinical  outcomes  between  patients  with  higher-normal
and  lower-normal  ALT  levels.8,9 It  remains  to  be  determined
whether  ALT  levels  near  the  ULN  warrant  management
changes  for  inactive  carriers.
2.2.  HBsAg  quantiﬁcation
The  HBV  marker  HBsAg  has  been  the  foundation  of  HBV  infec-
tion  diagnosis  since  its  discovery  over  40  years  ago;  however,
its  signiﬁcance  in  clinical  practice  has  mostly  been  limited  to
qualitative  status.  Recently,  interest  has  sparked  regarding
its  quantiﬁcation  as  an  important  diagnostic,  prognostic  and
predictive  tool.10
HBsAg  is  the  glycosylated  protein  of  the  HBV  virion
envelope.  The  DNA  template  for  HBV  replication  exists
in  hepatocytes’  nuclei  as  covalently  closed  circular  DNA
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cccDNA)  and  segments  of  it  can  become  integrated  in  the
ost’s  hepatocyte  genome.  Unlike  mature  virions,  HBsAg  can
lso  be  produced  from  integrated  HBV  DNA.  It  is  produced
n  excess  of  mature  virions  and  consequently  exists  in  circu-
ation  both  associated  with  virions  and  as  subviral  particles.
HBsAg  levels  tend  to  decline  as  disease  progresses  to
Be-negativity  and  inactivity  but  they  re-elevate  if  there  is
eactivation  to  active  hepatitis.11 Several  cross-
ectional12--14 and  longitudinal15--17 studies  have  also
emonstrated  a  signiﬁcant  difference  in  HBsAg  levels
etween  inactive  carriers  versus  active  HBe-negative
hronic  hepatitis,  revealing  its  potential  usefulness  in
iscriminating  between  them.  Using  a  HBsAg  cut-off  level
f  650  IU/mL,  Brunetto  et  al.  found  a  diagnostic  accuracy  of
8%  for  diagnosing  inactive  carriers  in  a population  of  209
talian  treatment-naïve  HBe-negative  genotype  D  infected
atients;  sensitivity,  speciﬁcity,  positive  predictive  value
PPV)  and  negative  predictive  value  (NPV)  were  82,  90,  75
nd  93%,  respectively.16
In  addition,  HBsAg  appears  to  have  prognostic  sig-
iﬁcance  for  both  HBsAg  seroclearance  and  disease
eactivation.  Lower  baseline  HBsAg  levels  and  yearly  HBsAg
ecline  are  independently  associated  with  subsequent
BsAg  loss.16 In  Taiwanese  HBe-negative  treatment-naïve
atients,  baseline  HBsAg  <50  IU/mL  could  predict  HBsAg  loss
uring  a median  follow-up  of  8  years  with  82%  sensitivity  and
7%  speciﬁcity.18 In  Korean  genotype  C-infected  inactive  car-
iers,  baseline  HBsAg  >  850  IU/mL  and  HBV  DNA  >850  IU/mL
ould  predict  reactivation  with  85%  accuracy,  65%  sensitivity,
3%  speciﬁcity,  80%  PPV  and  86%  NPV.15
Interestingly,  while  HBsAg  correlates  strongly  with  serum
BV  DNA  in  global  chronic  hepatitis  B  populations,13,19 cor-
elation  is  only  weak  in  HBe-negative  patients.12,15,20,21 It
ppears  HBsAg  levels  do  not  fall  in  the  same  proportion  as
BV  DNA  levels  as  disease  progresses.  Accordingly,  the  serum
BV  DNA/HBsAg  ratio  appears  to  be  signiﬁcantly  higher  in
ctive  CHB  versus  inactive  HBV  carriers.12,14,19,20
Indeed,  it  is  the  combination  of  serum  HBsAg  and  HBV
NA  levels  that  shows  most  promise  as  a single-point
easurement  for  differentiating  active  CHB  versus  inac-
ive  carriers.  A  single-point  measurement  of  serum  HBsAg
cut-off  <1000  IU/mL)  and  HBV  DNA  (cut-off  ≤2000  IU/mL)
n  the  abovementioned  Italian  population  achieved  even
etter  discriminatory  power  between  these  two  stages  of
hronic  HBV  infection  (94%  diagnostic  accuracy,  91%  sensi-
ivity,  95%  speciﬁcity,  88%  PPV,  97%  NPV).16 However,  Park
t  al.  tested  these  cut-offs  in  104  Korean  treatment-naïve
enotype  C  HBe-negative  patients  and  obtained  poorer  val-
es:  62%  diagnostic  accuracy,  55%  sensitivity,  77%  speciﬁcity,
5%  PPV  and  42%  NPV.15 Furthermore,  in  228  heterogeneous
BV-infected  European  patients,  active  hepatitis  preva-
ence  was  substantial  (28%)  even  when  HBsAg  levels  were
100  IU/mL,22 demonstrating  the  need  for  further  studies
n  larger  cohorts  of  HBV  infected  patients  with  different
haracteristics  before  a  clinically  useful  cut-off  level  is
chieved.
.3.  Liver  histologynactive  carriers  have  by  deﬁnition  minimal  to  no  necroin-
ammatory  activity  in  the  liver.  However,  because  liver
iopsy  is  seldom  recommended  in  these  patients,  this  is
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The  two  factors  most  consistently  associated  with  risk  of44  
arely  conﬁrmed  histologically.  Serial  liver  biopsies  are  even
ess  frequently  performed,  making  follow-up  of  liver  his-
ologic  changes  in  inactive  carrier  populations  difﬁcult  to
valuate.1
A  recent  review  raised  the  concern  that  in  approximately
0%  of  inactive  HBV  carriers  diagnosed  based  on  ALT  and  HBV
NA  levels  alone,  signiﬁcant  liver  disease  might  be  missed,23
ased  on  liver  biopsies  conducted  in  Indian  and  French  inac-
ive  carriers.
Indeed,  a  2012  systematic  review  of  6  studies  with  liver
istology  data  from  inactive  carriers  (which  included  the  two
bove-mentioned  studies)  concluded  that  mild  liver  necroin-
ammatory  activity  and  moderate  ﬁbrosis  were  present  in
0  and  8%  of  patients,  respectively,  when  PNALT  deﬁni-
ion  was  appropriate,  but  only  1.4  and  0.7%,  respectively,
hen  viremia  levels  <2000  IU/mL  were  also  a  diagnostic  cri-
erion.  In  contrast,  studies  with  poor  deﬁnitions  of  PNALT,
iremia  levels  >2000  IU/mL  and/or  signiﬁcant  baseline  liver
isease  found  a  higher  proportion  of  moderate  to  severe
iver  changes.24
Liver  biopsy  is  the  gold-standard  for  evaluation  of  dis-
ase  activity  and  liver  ﬁbrosis  in  HBV  infection;  however  it
s  invasive  and  observer-dependent  and  carries  a  small  risk  of
erious  complications,1 all  of  which  make  its  use  in  asymp-
omatic  patients  with  modest  clinical  alterations  open  to
uestion.
Transient  elastography  is  a  recent  simple  and  non-
nvasive  method  for  ﬁbrosis  assessment  based  on  liver
tiffness  measured  with  an  ultrasonographic  method.  It  has
een  shown  to  be  accurate  and  reproducible  in  hepatitis  B25
nd  might  supplant  liver  biopsy  in  assessing  ﬁbrosis  in  these
atients.
Liver  stiffness  is  signiﬁcantly  lower  in  true  inactive  car-
iers  (deﬁned  using  previous  cut-off  of  20,000  IU/mL)  than
n  HBe-negative  active  hepatitis  patients  and  was  similar  to
hat  of  healthy  controls  in  three  European  studies.26--28 In
nactive  carriers  and  untreated  HBe-negative  CHB  patients,
ts  diagnostic  accuracy  for  the  presence  of  Ishak  ﬁbrosis
core  ≥3  was  90.1%  (sensitivity,  93.9%;  speciﬁcity,  88.5%;
PV,  76.7%;  NPV,  97.3%)  and  94.2%  for  diagnosing  cirrho-
is  (sensitivity,  86.5%;  speciﬁcity,  96.3%;  PPV,  86.5%;  NPV,
6.3%).26 The  cut-offs  used  were  those  with  greater  areas
nder  ROC  curve  (AUROCs):  7.5  and  11.8  pKa  for  diagnosing
shak  ﬁbrosis  score  ≥3  and  cirrhosis,  respectively.  These  are
imilar  to  those  proposed  in  a  2012  systematic  review  of  het-
rogeneous  chronic  hepatitis  B  patients  (7.9  and  11.7  pKa
or  ﬁbrosis  METAVIR  score  ≥2  and  cirrhosis,  respectively).
he  same  review  points  out  that  transient  elastography  in
BV  infection  may  yield  false  results  under  certain  circum-
tances.  On  the  one  hand,  liver  stiffness  readings  increase
ith  active  hepatic  inﬂammation  and  false  positive  results
re  possible  if  there  is  ALT  elevation.  On  the  other,  false  neg-
tives  may  result  from  the  ultrasound  beam  missing  ﬁbrotic
ands,  especially  considering  the  macronodular  nature  of
irrhosis  in  HBV  infection.25
However,  there  is  another  important  aspect  other  than
he  staging  of  ﬁbrosis  that  could  reinforce  the  need  for  per-
orming  liver  biopsies  in  these  patients:  the  determination
f  the  amount  of  HBV  infected  hepatocytes,  which  currently
elies  on  a  liver  tissue  sample.  Nonetheless,  HBsAg  quantiﬁ-
ation  displays  some  promising  value  in  this  regard.  HBsAg
evels  have  been  shown  to  correlate  positively  with  cccDNA
r
o
aI.  Pita  et  al.
an  accurate  marker  of  the  burden  of  infected  liver  cells)  in
Be-positive  CHB  patients21,29 and  have  displayed  utility  in
redicting  and  monitoring  response  to  therapy.10,11,30 How-
ver,  studies  so  far  have  found  this  correlation  to  be  weaker
n  HBe-negative  HBV  infected  patients.21,29,31 Further  stud-
es  in  HBe-negative  populations  could  shed  some  light  on
BsAg  and  cccDNA  kinetics  during  later  phases  of  HBV
nfection.
. Natural history of HBV inactive carriers
mong  HBV-infected  patients,  the  inactive  carrier  state
enerally  has  a  very  good  prognosis;  however,  reactivation
f  active  hepatitis,  cirrhosis  and  hepatocellular  carcinoma
HCC)  are  rare  but  nevertheless  possible  complications.
.1.  Spontaneous  reactivation
isease  progression  to  HBe-negative  active  hepatitis  with
r  without  reversion  to  HBeAg  positivity  is  a  possible  out-
ome  for  inactive  carriers;  this  may  happen  spontaneously,
r  following  immunosuppressant  therapy  or  disease.
Spontaneous  relapse  of  hepatitis  and  reversion  to  HBe-
ositivity  have  been  extensively  studied  in  prospective
tudies  of  HBe-negative  patients.  A  recent  review  by  Villa
t  al.  has  highlighted  that  discordant  relapse  rates  appear  to
tem  from  different  study  designs  and  populations.  In  stud-
es  of  non-endemic  populations,  incidence  of  reactivation
anged  from  0.03  to  0.8  per  100  person-years,  whereas  this
ncidence  was  somewhat  higher  in  endemic  areas  (1.4--2.8
er  100  person-years).  Relapse  rate  also  seemed  to  vary
ccording  to  sampling  method:  when  patients  were  studied
fter  recent  seroconversion  to  HBe-negativity  during  follow-
p,  incidence  of  reactivation  ranged  from  0.8  to  2.8  per
00  person-years,  whereas  those  who  were  already  HBe-
egative  at  enrollment  had  reactivation  rates  of  0.08  to  1.4
er  100  person-years.  The  authors  conclude  that  longer  time
rom  seroconversion  may  account  for  this  lower  incidence  of
eactivation.23
Accordingly,  in  asymptomatic  HBe-negative  Taiwanese
atients,  cumulative  incidences  of  relapse  were  10.2,  17.4,
9.3  and  20.2%  at  5,  10,  15  and  20  years,  respectively.  The
ncreases  in  cumulative  incidence  tended  to  be  progressively
ower  as  time  went  on,  with  approximately  half  of  relapses
ccurring  during  the  ﬁrst  5  years  of  follow-up.32 Both  these
ata  suggest  that  risk  of  spontaneous  reactivation  tends  to
ecrease  with  time  from  seroconversion.
However,  studying  the  rate  of  spontaneous  relapse  in
rue  inactive  carriers  proves  more  difﬁcult  because  only  a
ew  longitudinal  studies  correctly  diagnose  them  with  regu-
ar  ALT  and  HBV  DNA  measurements  during  one  year  before
eginning  follow-up.
Incidence  rates  from  three  prospective  studies  in  which
nactive  carrier  state  were  deﬁned  after  at  least  6  months
f  persistently  normal  ALT  are  summarized  in  Table  1,  as
ell  as  data  from  three  additional  studies  on  asymptomatic
Be-negative  patients  with  normal  ALT.elapse  in  HBe-negative  patients  are  male  gender32--35 and
lder  age  at  HBe  seroconversion.32,34,35 Other  patient  char-
cteristics  that  seem  to  confer  greater  risk  of  reactivation
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re  baseline  ALT  and  HBV  DNA  levels,36 maximum  ALT  dur-
ng  follow-up,  genotype  C35 and  endemic  geographic  area.23
t  is  possible  that  HBV  primo-infection  at  a  very  young  age
ccounts  for  the  higher  reactivation  rate  in  endemic  popula-
ions,  where  transmission  occurs  most  commonly  perinatally
nd  in  early  childhood.2
A  study  on  true  inactive  carriers  found  no  statistically  sig-
iﬁcant  difference  in  the  age  and  sex  between  true  inactive
arriers  who  remained  so  and  those  who  reactivated;  how-
ver,  the  latter  had  signiﬁcantly  higher  baseline  serum  ALT
nd  HBV  DNA.36
.2.  Non-spontaneous  reactivation
eactivation  of  active  hepatitis  in  inactive  HBV  carriers
including  HBsAg-negative  anti-HBs-positive  patients)  has
een  observed  during  or  after  cytotoxic  treatments  for
alignancies.  It  is  most  often  asymptomatic,  but  a hepati-
is  ﬂare  with  hepatic  decompensation  and  even  death  can
ccur  in  5--40%  of  cases.37 It  appears  to  be  more  common
hen  corticosteroids,  anthracyclines  or  rituximab  are  part
f  the  treatment  regimen.37,38 Reactivation  has  also  been
escribed  in  association  with  imunossupressive  drugs  used
n  rheumatic  and  autoimmune  diseases,  including  cortico-
teroids,  methotrexate  and  anti-TNF  drugs.39
Major  guidelines  therefore  recommend  prophylactic
enofovir  or  entecavir  for  all  HBsAg  carriers  during  any  cyto-
oxic  or  imunossupressive  treatment  and  for  6--12  months
hereafter.1,5 For  HBV-infected  patients  who  have  cleared
BsAg  and  have  detectable  serum  HBV  DNA  (occult  HBV
nfection),  the  EASL  recommends  similar  prophylaxis;  on  the
ther  hand,  if  HBV  DNA  is  undetectable,  either  prophylaxis
ith  lamivudine  or  strict  follow-up  with  ALT  and  HBV  DNA
evels  every  1--3  months  are  appropriate  approaches.
The  natural  history  of  inactive  carriers  is  also  inﬂu-
nced  by  human  immunodeﬁciency  virus  (HIV)  co-infection.
n  general,  untreated  HIV  infection  is  associated  with  higher
BV  replication,  higher  reactivation  rate  and  reduced  liver
ecroinﬂammatory  activity  in  comparison  with  HBV  infec-
ion  alone,  probably  due  to  CD4+  cell  depletion  and  immune
ystem  impairment.  Initiation  of  highly  active  antiretrovi-
al  therapy  may  help  immune  control  of  viral  replication,
ut  it  is  also  associated  with  hepatitis  reactivation  due  to
he  immune  reconstitution  syndrome.40 Still,  inactive  carrier
tate  alone  does  not  mandate  any  changes  in  HIV  infection
reatment  according  to  the  European  AIDS  Clinical  Society
uidelines.41
.3.  Spontaneous  clearance
he  annual  rate  of  HBsAg  clearance  among  heterogeneous
BsAg  carriers  is  0.5%.5 This  is  considered  the  best  pos-
ible  outcome  of  HBV  infection;  however,  residual  viral
eplication  can  persist  and  HBV  DNA  is  detectable  in  the
iver  even  decades  later.42
Table  2  summarizes  incidences  of  HBsAg  loss  from  three
ongitudinal  studies  in  HBe-negative  patients  with  baseline
ormal  ALT.43--45 Only  one  of  them  discriminated  results  from
rue  inactive  carriers  classiﬁed  after  one  year  of  PNALT  and
he  higher  HBsAg  seroclearance  rate  in  this  population  pos-
ibly  reﬂects  that.44
246  I.  Pita  et  al.
Table  2  Incidence  of  HBsAg  loss  in  HBe-negative  HBsAg  carriers  with  normal  baseline  ALT.
Author  (date)  Geographic
area
No.  of
patients
%  of  males  Mean  follow-up
(years)
No.  HBs  clearance
(%)
Incidence  rate  (per  100
person-years)
Tong  and  Trieu
(2013)43
USA  146  47  8  13  (9)  1.1
Martinot-Peignoux
et al.  (2013)44
France  54  n.a.  10  8  (15)  1.5
Chu and  Liaw
(2007)45
Taiwan  1965  55  10.8  245  (12)  1.2
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5HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase
Yuen  et  al.  have  extensively  elucidated  the  natural  his-
ory  of  disease  after  HBsAg  clearance  in  a  longitudinal
tudy  of  298  heterogeneous  HBV-infected  patients  followed
or  a  median  of  3  years  after  HBsAg  loss  (96%  of  it  spon-
aneous).  All  became  HBe-negative  before  clearing  HBsAg
nd  52%  of  them  developed  anti-HBsAg.  In  a  subset  of  212
atients  who  had  at  least  4  ALT  measurements,  82%  main-
ained  PNALT  during  the  rest  of  follow-up;  in  those  who
id  not  (18%),  alternative  causes  for  transaminase  eleva-
ion  other  than  active  HBV  hepatitis  were  present  in  all
ut  6  (2.8%)  of  patients  (fatty  liver,  hepatocellular  carci-
oma  or  intake  of  potentially  hepatotoxic  traditional  herbal
edicines).  The  number  of  patients  with  detectable  serum
BV  DNA  diminished  with  time  from  seroclearance;  how-
ver,  integrated  HBV  DNA  remained  detectable  in  all  29  liver
iopsies  performed  and  cccDNA  in  23.  There  were  5  clinical
omplications  of  cirrhosis  (all  with  HBsAg  clearance  after
7  years  of  age;  3  had  transient  elastography  readings  com-
atible  with  cirrhosis  within  1  year  of  seroclearance)  and  7
atients  developed  HCC  (all  were  men  and  lost  HBsAg  aged
50  years;  6  had  cirrhosis  on  ultrasound  within  1  year  of
eroclearance).42
It  seems  HBsAg  loss  is  associated  with  improved  prognosis
articularly  when  no  cirrhosis  has  yet  developed  and  with
ounger  age  at  seroclearance.
.4.  Complications  and  survival
tudying  the  incidence  of  liver  complications  in  inactive  car-
iers  is  likewise  hindered  by  the  small  number  of  prospective
tudies  which  correctly  deﬁne  this  state.  In  two  longitudi-
al  studies  of  strictly  deﬁned  inactive  carriers  followed  for
 median  of  3.2  and  5.3  years,  none  developed  cirrhosis  or
CC  (Table  3).33,46 Another  study  on  145  true  inactive  car-
iers  with  a  longer  follow-up  (mean  of  8  years)  found  two
nstances  of  HCC  and  no  cases  of  liver-related  death.43
In  a  larger  scale  sample  of  1932  Taiwanese  inactive  car-
iers,  annual  rates  of  HCC  and  liver-related  mortality  were
.06  and  0.04%,  respectively.  Serum  HBV  DNA  level  was  the
ost  important  predictor  of  both  outcomes.  Interestingly,
ts  prognostic  value  for  HCC  was  greater  in  HBe-negative
atients  with  normal  ALT  and  no  cirrhosis  when  compared
ith  the  whole  HBsAg-positive  cohort;  this  greater  associ-
tion  was  not  found  for  prediction  of  cirrhosis.47 Another
tudy  on  the  same  population  found  older  age  and  alcohol
onsumption  to  be  predictors  of  HCC  and  liver-related  death
n  inactive  carriers;  on  the  contrary,  no  statistically  signiﬁ-
H
B
iant  difference  in  outcomes  was  demonstrated  for  gender,
moking  habits  and  high-normal  vs.  low-normal  ALT  levels  in
nactive  carriers.9
. Management of inactive carriers
ue  to  its  general  excellent  prognosis,  antiviral  treatment  is
ot  generally  recommended  for  HBV  patients  in  the  inactive
arrier  state.
Once  true  inactive  carrier  state  is  conﬁrmed,  regu-
ar  lifelong  monitoring  with  ALT  levels  every  6--12  months
nd  periodic  HBV  DNA  measurements  is  advised.1 Because
iver  biopsy  is  not  routinely  advised  in  inactive  carriers,
epatic  ﬁbrosis  remains  uninvestigated  during  the  follow-up
f  most  of  these  patients.  To  this  end,  transient  elastogra-
hy  appears  an  advantageous  ﬁbrosis  assessment  tool  that
an  easily  be  used  for  baseline  and  even  serial  monitoring
f  liver  ﬁbrotic  changes.
Decision  to  treat  patients  with  ALT  >  twice  the  upper  limit
f  normal  (ULN)  and  HBV  DNA  >20,000  IU/mL  is  unanimous1,5
ut  it  is  less  ﬁrm  when  ALT  is  minimally  elevated  (<2ULN)
nd/or  HBV  DNA  levels  are  between  20,000  and  2000  IU/mL.
atients  with  normal  ALT  and  HBV  DNA  levels  between  2000
nd  20,000  IU/mL  (the  aforementioned  HBV  DNA  level  ‘‘gray
rea’’)  should  be  followed  more  closely  with  ALT  determi-
ations  every  3  months  for  at  least  three  years,  because
s  previously  discussed,  relapse  to  active  hepatitis  appears
ore  likely  during  the  beginning  of  follow-up.23,32 Indeed,
n  a study  of  217  HBe-negative  asymptomatic  patients  with
ormal  baseline  ALT,  time  to  reactivation  (deﬁned  as  ALT
nd  HBV  DNA  elevation)  after  beginning  of  follow-up  was
nalyzed:  the  10th  percentile  was  3.4  months,  which  sug-
ests  that  analytical  assessment  of  inactive  carriers  every
 months  can  detect  approximately  90%  of  relapses.34
hen  there  are  only  small  ALT  or  HBV  DNA  elevations
ALT  <  2  ×  ULN  or  HBV  DNA  <20,000  IU/mL),  guidelines  also
uggest  liver  biopsy5 or  transient  elastography1 to  assess
everity  of  disease  before  decision  to  treat  is  made.
Though  a rare  complication,  HCC  is  a  possible  life-
hreatening  event;  however,  guidelines  only  recommend
creening  in  high-risk  patients.1,5
. DiscussionBsAg  inactive  carriers  represent  the  majority  of  hepatitis
 virus  carriers  who  have  seroconverted  to  anti-HBe,5 mak-
ng  them  an  especially  important  subpopulation  of  chronic
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Table  3  Liver-related  outcomes  in  inactive  carriers  (incidence  per  100  person-years).
Author  (date)  Geographic
area
No.
patientsa
%  of  males  Follow-up
(years)
HCC
incidence
Liver-related  mortality
incidence
Tong  and  Trieu
(2013)43
USA  146b 47  8  0.17  0
Chen et  al.  (2010)9 Taiwan  1932  58  13.1  0.06  0.04
Zacharakis  et  al.
(2008)46
Greece  195  n.a.  5.3  0  0d
Martinot-Peignoux
et  al.  (2002)33
France  85c 54  3.2 0d 0d
HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; HCC, hepatocellular carcinoma.
a Inactive carriers deﬁned as HBe-negative HBsAg carriers with normal baseline ALT and HBV DNA <2000 IU/mL unless otherwise
speciﬁed.
b 24 patients became inactive carriers after antiviral treatment.
c 16 patients had HBV DNA >2000 IU/mL; 2 > 20,000 IU/mL.
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HBV  patients,  both  due  to  their  signiﬁcant  number  but  also
because  of  the  particularities  in  their  management.  Speciﬁ-
cally,  they  are  not  candidates  for  any  of  the  current  hepatitis
B  therapies  available.
The  clinician’s  main  goals  when  faced  with  an  inac-
tive  carrier  must  be  (A)  conﬁrming  inactive  carrier  status,
(B)  monitoring  for  reactivation  and  (C)  screening  for  liver
complications.5 We  will  comment  on  each  of  these  items
separately.
5.1.  Conﬁrming  inactive  carrier  status
Debate  continues  regarding  the  most  recent  update  of  low-
ering  the  HBV  DNA  cut-off  level  to  2000  IU/mL  for  diagnosing
inactive  carriers.  One  study  counter-argues  this  cut-off
alteration  with  the  evidence  that  23%  of  inactive  carriers
diagnosed  after  one  year  of  PNALT  had  at  least  one  HBV
DNA  measurement  between  2000  and  20,000  IU/mL  during  a
median  follow-up  of  3  years.36 The  new  cut-off  level  would
therefore  leave  one-ﬁfth  of  these  probable  inactive  carri-
ers  robbed  of  this  classiﬁcation  while  still  not  fulﬁlling  the
criteria  for  chronic  active  hepatitis.  However,  we  believe
that  this  particular  subset  of  patients  has  an  important  risk
of  active  disease  and  according  to  guidelines  warrants  dif-
ferent  management  from  true  inactive  carriers,  deserving
therefore  clinical  distinction.  Guideline  recommendations
for  these  patients  vary  between  tighter  follow-up  (with  ALT
determination  every  3  months  and  HBV  DNA  measurements
every  6--12  months  for  3  years)  and  liver  ﬁbrosis  assessment
(with  a  non-invasive  method  such  as  transient  elastography
or  even  liver  biopsy).1,5 As  such,  a  cut-off  level  of  2000  IU/mL
seems  to  us  more  useful  clinically:  even  though  it  is  more
speciﬁc  for  inactive  carriers,  it  is  less  likely  to  misdiagnose
patients  with  active  disease  who  might  beneﬁt  from  antiviral
treatment.
In  recent  years,  HBsAg  quantiﬁcation  has  been  gaining
prominence  as  a  tempting  substitute  for  the  yearlong  follow-
up  necessary  to  diagnose  inactive  carriers.  As  a  standalone
single-point  test,  an  HBsAg  level  <1000  IU/mL  demonstrated
good  discriminatory  power  for  diagnosing  inactive  carrier
state  in  a  European  population;  diagnostic  power  was  even
stronger  when  associated  with  a  same  time-point  HBV  DNA
o
i
Aevel  <2000  IU/mL.16 Even  though  these  cut-off  levels  remain
o  be  tested  and  validated  in  different  hepatitis  B  patient
ohorts,  quantitative  HBsAg  seems  a very  promising  diagnos-
ic  marker.
HBsAg  levels  are  generally  correlated  with  viremia,  but
n  low  replicative  states  such  as  inactive  carrier  state,
hey  remain  proportionally  higher  to  those  of  serum  HBV
NA,21,29,31 probably  reﬂecting  HBsAg  secretion  from  inte-
rated  HBV  DNA  and/or  reduced  host  immune  control  over
BsAg  production  versus  viral  replication.  It  provides  addi-
ional  information  about  the  patient’s  immune  control  over
he  disease  and  possibly  about  the  extent  of  affected  hepa-
ocytes:  HBsAg  loss  represents  optimal  viral  suppression  and
ower  HBsAg  levels  as  well  as  higher  rate  of  HBsAg  decline
uring  the  course  of  the  disease  appear  to  be  predictive  of
his  outcome.16,18
As  for  the  assessment  of  liver  ﬁbrosis  in  this  subset  of
BV-infected  patients,  it  seems  to  us  that  despite  being  the
old-standard,  liver  biopsy  does  not  constitute  an  optimal
rst-line  exam  in  this  population,  mainly  because  it  is  inva-
ive,  observer-dependent  and  carries  a small  risk  of  serious
omplications,  making  its  use  in  asymptomatic  patients  with
ow  risk  of  severe  liver  disease  very  questionable.
When  available,  liver  transient  elastography  represents
 more  convenient  screening  test,  both  for  health-care
roviders  and  patients,  in  diagnosing  inactive  carriers  and
ven  serially  monitoring  their  degree  of  ﬁbrosis.  Liver  biopsy
hould  be  reserved  for  patients  with  unexplained  ALT  ele-
ations  of  >2  ×  ULN,  isolated  viremia  of  >20,000  IU/mL  or
bnormal  liver  stiffness  measurements.
.2.  Monitoring  for  reactivation
here  are  few  prospective  studies  of  inactive  carriers
eﬁned  according  to  the  most  recent  guidelines.  Still,  prog-
osis  and  outcomes  are  decidedly  favorable  in  asymptomatic
BsAg  carriers  with  normal  ALT  levels  and  low  viremia.
Reactivation  rates  in  true  inactive  carriers  are  a  very  rare
utcome:  incidences  were  0.8  and  0.4  per  100  person-years
n  two  studies  from  France  and  Greece,  respectively.33,36
nother  Greek  study  revealed  a  surprising  reactivation  rate
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f  4.7  per  100  person-years.46 Even  though  no  signiﬁcant
ifferences  in  study  design  or  population  sampling  method
ere  reported,  it  is  possible  that  in  this  study  undisclosed
lcohol  consumption  or  unidentiﬁed  advanced  liver  disease
t  baseline  (no  initial  liver  biopsies  were  performed)  may
ccount  for  this  discrepancy.
Most  longitudinal  studies  investigating  reactivation  in
nactive  carriers  fail  to  mention  HBeAg  reversion  rates;  in
hose  who  do,  these  are  negligible  (0--0.07  per  100  person-
ears).33,34
Monitoring  for  relapse  of  active  hepatitis  can  be  accom-
lished  with  regular  ALT  and  HBV  DNA  measurements.  As
entioned  previously,  HBV  DNA  elevations  between  2000
nd  20,000  IU/mL  do  not  necessarily  correspond  to  disease
ctivity:  these  patients  beneﬁt  from  more  frequent  follow-
p  to  clarify  this.  In  isolated  viremia  in  this  range  with
ersistently  normal  ALT  levels,  liver  ﬁbrosis  stage  should  be
nvestigated  with  transient  elastography,  since  active  liver
nﬂammation  is  an  unlikely  confounding  factor.  Conversely,
solated  ALT  elevations  <2ULN  may  beneﬁt  more  from  liver
iopsy  to  exclude  other  causes  of  raised  transaminase  levels,
uch  as  alcohol  abuse,  hepatic  steatosis  or  HCC.
.3.  Liver  complications
irrhosis  and  hepatocellular  carcinoma  are  rare  but  possible
utcomes  even  after  years  of  inactive  disease  and  even  after
BsAg  loss.9,43 Higher  HBV  DNA  levels  (within  inactive  carrier
ange),  older  age  and  alcohol  consumption  were  found  to  be
isk  factors  for  both  complications  in  this  subpopulation.  It  is
nteresting  to  note  that  HBV  DNA  has  a  proportionally  greater
redictor  effect  for  HCC  in  inactive  carriers  compared  to
BV  chronic  hepatitis  in  general,  demonstrating  the  rele-
ance  of  a  viral-dependent,  rather  than  ﬁbrosis-dependent,
ncogenic  pathway  in  these  patients.9,47
In  conclusion,  we  consider  hepatitis  B  inactive  carrier
tate  a  relatively  benign  condition  in  the  HBV  infection
pectrum,  but  only  if  accurately  diagnosed.  Transient  elas-
ograhy  and  the  promising  HBsAg  quantiﬁcation  in  serum  are
he  two  most  recent  major  advances  that  have  contributed
o  more  accurate  diagnosis  of  this  state  and  simpliﬁed
ts  follow  up,  obviating  the  need  for  biopsy  in  many  cir-
umstances.  After  correct  diagnosis,  lifelong  monitoring  is
arranted  for  early  detection  of  possible  reactivation  and
epatic  complications.  The  goal  in  clinical  practice  is  to
ecognize  all  situations  which  mandate  a  change  in  man-
gement  (be  it  with  tighter  follow-up,  further  investigations
r  treatment),  so  it  can  be  implemented  as  soon  as  possi-
le  in  order  to  minimize  liver  damage  and  negative  clinical
utcomes.
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